Home > BRISA > Search result
COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 5

Informe diário de evidências COVID-19: busca realizada entre 6 e 8 de junho de 2020

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde.
O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao di...
Coronavirus Infections/drug therapy, Pneumonia, Viral/drug therapy, Betacoronavirus/drug effects, Autohemotherapy, Pneumococcal Vaccines, Influenza Vaccines, BCG Vaccine, Immunoglobulins/therapeutic use, Famotidine/therapeutic use, gamma-Globulins/therapeutic use, Methylprednisolone/therapeutic use, Chloroquine/therapeutic use, Lopinavir/therapeutic use, Ritonavir/therapeutic use, Interferon-alpha/therapeutic use, Acetylcysteine/therapeutic use, Colchicine/therapeutic use, Nitric Oxide/therapeutic use, Observational Study, Technology Assessment, Biomedical
Fulltext

Estudio de costo efectividad de la vacuna neumocócica conjugada 10-valente (PCV10) versus la vacuna neumocócica: conjugada 13-valente (PCV13) en el Ecuador

Ecuador. Ministerio de Salud Pública. Coordinación General de Desarrollo Estratégico en Salud.
INTRODUCCIÓN: El Streptococcus pneumoniae es la principal causante de patologías como: neumonía, meningitis y otras enfermedades invasivas, especialmente en niños <5 años de edad en países en vías de desarrollo. Las enfermedades causadas por Streptococcus pneumoniae o neumococo, son una de las pri...
Vaccines, Conjugate/therapeutic use, Pneumococcal Vaccines/therapeutic use, Pneumonia/drug therapy, Meningitis/drug therapy, Technology Assessment, Biomedical, Cost-Benefit Analysis/economics, Ecuador
Fulltext

Eficácia, segurança e custo-efetividade da vacina pneumo-13-valente

Centro Colaborador do SUS. Avaliação de Tecnologias e Excelência em Saúde.
TECNOLOGIA: Vacina pneumocócica conjugada 13-valente (PCV13). INDICAÇÃO: Proteção de crianças entre 6 semanas e 6 anos de idade, contra os sorotipos (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F e 23F) da bactéria Streptococcus pneumoniae (S.pneumoniae), causadora de doenças pneumocócicas como ...
Pneumococcal Infections/prevention & control, Pneumococcal Vaccines/administration & dosage, Heptavalent Pneumococcal Conjugate Vaccine/administration & dosage, Technology Assessment, Biomedical, Cost-Benefit Analysis/economics, Brazil/epidemiology
Fulltext

A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries

Martí, Sebastián García; Colantonio, Lisandro; Bardach, Ariel; Galante, Julieta; Lopez, Analía; Caporale, Joaquín; Knerer, Gerhart; Gomez, Jorge Alberto; Augustovski, Federico; Pichon-Riviere, Andrés.
Cost effectiveness and resource allocation; 11 (1), 2013
BACKGROUND: A recently developed 10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) is expected to afford protection against more than two thirds of isolates causing IPD in children in Latin America, and also against acute otitis media caused by both Spn and NTHi. T...
Pneumococcal Vaccines/analysis, Streptococcus pneumoniae/immunology, Cost-Benefit Analysis/economics, Vaccines, Conjugate, Technology Assessment, Biomedical, Health Evaluation, Argentina, Brazil, Chile, Colombia, Mexico, Peru
Fulltext

Estudio de costo efectividad para la vacuna conjugada contra el neumococo en la Argentina

Argentina. Ministerio de Salud; Organización Panamericana de la Salud.
Objetivos: Evaluar las mejoras previstas en salud, costos incrementales del programa de vacunación, costos prevenidos en el sistema de salud y costo-efectividad de la introducción de diferentes vacunas conjugadas contra el neumococo, en población pediátrica en la Argentina. Construir un documento té...
Pneumonia, Pneumococcal/prevention & control, Pneumococcal Vaccines/economics, Vaccines, Conjugate, Cost-Benefit Analysis, Cohort Studies, Argentina, Health Information Systems
Fulltext